---
input_text: "Interventions for preventing silent cerebral infarcts in people with
  sickle cell disease. BACKGROUND: Sickle cell disease (SCD) is one of the commonest
  severe monogenic disorders in the world, due to the inheritance of two abnormal
  haemoglobin (beta globin) genes. SCD can cause severe pain, significant end-organ
  damage, pulmonary complications, and premature death. Silent cerebral infarcts are
  the commonest neurological complication in children and probably adults with SCD.
  Silent cerebral infarcts also affect academic performance, increase cognitive deficits
  and may lower intelligence quotient. OBJECTIVES: To assess the effectiveness of
  interventions to reduce or prevent silent cerebral infarcts in people with SCD.
  SEARCH METHODS: We searched for relevant trials in the Cochrane Library, MEDLINE
  (from 1946), Embase (from 1974), the Transfusion Evidence Library (from 1980), and
  ongoing trial databases; all searches current to 14 November 2019. We searched the
  Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register: 07 October
  2019. SELECTION CRITERIA: Randomised controlled trials comparing interventions to
  prevent silent cerebral infarcts in people with SCD. There were no restrictions
  by outcomes examined, language or publication status. DATA COLLECTION AND ANALYSIS:
  We used standard Cochrane methodological procedures. MAIN RESULTS: We included five
  trials (660 children or adolescents) published between 1998 and 2016. Four of the
  five trials were terminated early. The vast majority of participants had the haemoglobin
  (Hb)SS form of SCD. One trial focused on preventing silent cerebral infarcts or
  stroke; three trials were for primary stroke prevention and one trial dealt with
  secondary stroke prevention. Three trials compared the use of regular long-term
  red blood cell transfusions to standard care. Two of these trials included children
  with no previous long-term transfusions: one in children with normal transcranial
  doppler (TCD) velocities; and one in children with abnormal TCD velocities. The
  third trial included children and adolescents on long-term transfusion. Two trials
  compared the drug hydroxyurea and phlebotomy to long-term transfusions and iron
  chelation therapy: one in primary prevention (children), and one in secondary prevention
  (children and adolescents). The quality of the evidence was moderate to very low
  across different outcomes according to GRADE methodology. This was due to trials
  being at high risk of bias because they were unblinded; indirectness (available
  evidence was only for children with HbSS); and imprecise outcome estimates. Long-term
  red blood cell transfusions versus standard care Children with no previous long-term
  transfusions and higher risk of stroke (abnormal TCD velocities or previous history
  of silent cerebral infarcts) Long-term red blood cell transfusions may reduce the
  incidence of silent cerebral infarcts in children with abnormal TCD velocities,
  risk ratio (RR) 0.11 (95% confidence interval (CI) 0.02 to 0.86) (one trial, 124
  participants, low-quality evidence); but make little or no difference to the incidence
  of silent cerebral infarcts in children with previous silent cerebral infarcts on
  magnetic resonance imaging and normal or conditional TCDs, RR 0.70 (95% CI 0.23
  to 2.13) (one trial, 196 participants, low-quality evidence). No deaths were reported
  in either trial. Long-term red blood cell transfusions may reduce the incidence
  of: acute chest syndrome, RR 0.24 (95% CI 0.12 to 0.49) (two trials, 326 participants,
  low-quality evidence); and painful crisis, RR 0.63 (95% CI 0.42 to 0.95) (two trials,
  326 participants, low-quality evidence); and probably reduces the incidence of clinical
  stroke, RR 0.12 (95% CI 0.03 to 0.49) (two trials, 326 participants, moderate-quality
  evidence). Long-term red blood cell transfusions may improve quality of life in
  children with previous silent cerebral infarcts (difference estimate -0.54; 95%
  confidence interval -0.92 to -0.17; one trial; 166 participants), but may have no
  effect on cognitive function (least squares means: 1.7, 95% CI -1.1 to 4.4) (one
  trial, 166 participants, low-quality evidence). Transfusions continued versus transfusions
  halted: children and adolescents with normalised TCD velocities (79 participants;
  one trial) Continuing red blood cell transfusions may reduce the incidence of silent
  cerebral infarcts, RR 0.29 (95% CI 0.09 to 0.97 (low-quality evidence). We are very
  uncertain whether continuing red blood cell transfusions has any effect on all-cause
  mortality, Peto odds ratio (OR) 8.00 (95% CI 0.16 to 404.12); or clinical stroke,
  RR 0.22 (95% CI 0.01 to 4.35) (very low-quality evidence). The trial did not report:
  comparative numbers for SCD-related adverse events; quality of life; or cognitive
  function. Hydroxyurea and phlebotomy versus transfusions and chelation Primary prevention,
  children (121 participants; one trial) We are very uncertain whether switching to
  hydroxyurea and phlebotomy has any effect on: silent cerebral infarcts (no infarcts);
  all-cause mortality (no deaths); risk of stroke (no strokes); or SCD-related complications,
  RR 1.52 (95% CI 0.58 to 4.02) (very low-quality evidence). Secondary prevention,
  children and adolescents with a history of stroke (133 participants; one trial)
  We are very uncertain whether switching to hydroxyurea and phlebotomy has any effect
  on: silent cerebral infarcts, Peto OR 7.28 (95% CI 0.14 to 366.91); all-cause mortality,
  Peto OR 1.02 (95%CI 0.06 to 16.41); or clinical stroke, RR 14.78 (95% CI 0.86 to
  253.66) (very low-quality evidence). Switching to hydroxyurea and phlebotomy may
  increase the risk of SCD-related complications, RR 3.10 (95% CI 1.42 to 6.75) (low-quality
  evidence). Neither trial reported on quality of life or cognitive function. AUTHORS'
  CONCLUSIONS: We identified no trials for preventing silent cerebral infarcts in
  adults, or in children who do not have HbSS SCD. Long-term red blood cell transfusions
  may reduce the incidence of silent cerebral infarcts in children with abnormal TCD
  velocities, but may have little or no effect on children with normal TCD velocities.
  In children who are at higher risk of stroke and have not had previous long-term
  transfusions, long-term red blood cell transfusions probably reduce the risk of
  stroke, and other SCD-related complications (acute chest syndrome and painful crises).
  In children and adolescents at high risk of stroke whose TCD velocities have normalised,
  continuing red blood cell transfusions may reduce the risk of silent cerebral infarcts.
  No treatment duration threshold has been established for stopping transfusions.
  Switching to hydroxyurea with phlebotomy may increase the risk of silent cerebral
  infarcts and SCD-related serious adverse events in secondary stroke prevention.
  All other evidence in this review is of very low-quality."
raw_completion_output: |-
  primary_disease: Sickle cell disease (SCD)

  medical_actions: Preventing silent cerebral infarcts; Regular long-term red blood cell transfusions; Use of hydroxyurea; Phlebotomy; Iron chelation therapy

  symptoms: Severe pain; Significant end-organ damage; Pulmonary complications; Premature death; Affect academic performance; Increase cognitive deficits; Lower intelligence quotient; Acute chest syndrome; Painful crisis; Clinical stroke

  chemicals: Hydroxyurea

  action_annotation_relationships: Regular long-term red blood cell transfusions TREATS incidence of silent cerebral infarcts IN Sickle cell disease (SCD); Regular long-term red blood cell transfusions TREATS acute chest syndrome IN Sickle cell disease (SCD); Regular long-term red blood cell transfusions TREATS painful crisis IN Sickle cell disease (SCD); Regular long-term red blood cell transfusions TREATS clinical stroke IN Sickle cell disease (SCD); Use of hydroxyurea (with phlebotomy) INCREASES risk of silent cerebral infarcts IN Sickle cell disease (SCD); Use of hydroxyurea (with phlebotomy) INCREASES risk of SCD-related serious adverse events IN Sickle cell disease (SCD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Use of hydroxyurea (with phlebotomy) INCREASES risk of SCD-related serious adverse events IN Sickle cell disease (SCD)

  ===

extracted_object:
  primary_disease: MONDO:0007374
  medical_actions:
    - Preventing silent cerebral infarcts
    - Regular long-term red blood cell transfusions
    - Use of hydroxyurea
    - Phlebotomy
    - Iron chelation therapy
  symptoms:
    - Severe pain
    - Significant end-organ damage
    - Pulmonary complications
    - Premature death
    - Affect academic performance
    - Increase cognitive deficits
    - Lower intelligence quotient
    - Acute chest syndrome
    - Painful crisis
    - Clinical stroke
  chemicals:
    - CHEBI:44423
  action_annotation_relationships:
    - subject: red blood cell transfusions
      predicate: TREATS
      object: incidence of silent cerebral infarcts
      qualifier: MONDO:0007374
      subject_qualifier: Regular long-term
    - subject: red blood cell transfusions
      predicate: TREATS
      object: acute chest syndrome
      qualifier: MONDO:0007374
      subject_qualifier: long-term
    - subject: <Regular long-term red blood cell transfusions>
      predicate: <TREATS>
      object: <painful crisis>
      qualifier: MONDO:0007374
      subject_extension: <red blood cell>
    - subject: <blood transfusion>
      predicate: <TREATS>
      object: <clinical stroke>
      qualifier: MONDO:0007374
      subject_qualifier: <Regular long-term>
      subject_extension: <red blood cell>
    - subject: Use of hydroxyurea (with phlebotomy)
      predicate: INCREASES risk of
      object: silent cerebral infarcts
      qualifier: MONDO:0007374
      subject_qualifier: with phlebotomy
      subject_extension: CHEBI:44423
    - subject: Use of hydroxyurea (with phlebotomy)
      predicate: INCREASES risk of
      object: SCD-related serious adverse events
      qualifier: MONDO:0007374
      subject_extension: CHEBI:44423
named_entities:
  - id: MONDO:0011382
    label: Sickle Cell Disease
  - id: MAXO:0000457
    label: Pain Management
  - id: HP:0012531
    label: Pain
  - id: HP:0000739
    label: anxiety
  - id: MONDO:0005812
    label: Influenza
  - id: MAXO:0001017
    label: vaccination
  - id: MAXO:0000756
    label: transfusion
  - id: MONDO:0018881
    label: Myelodysplasia
  - id: MONDO:0000984
    label: Thalassemia
  - id: MONDO:0018373
    label: avascular necrosis (AVN)
  - id: MAXO:0009047
    label: total hip replacement (THR)
  - id: HP:0010885
    label: avascular necrosis
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: CHEBI:131923
    label: Salubrinal
  - id: MAXO:0000068
    label: Transplantation
  - id: CHEBI:44423
    label: hydroxyurea
  - id: MONDO:0003664
    label: Haemolytic Anaemias
  - id: HP:0032654
    label: Endothelial dysfunction
  - id: HP:0025464
    label: Oxidative stress
  - id: MAXO:0001298
    label: therapies
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: Arginine
  - id: CHEBI:18211
    label: Citrulline
  - id: CHEBI:3638
    label: Chloroquine
  - id: CHEBI:50733
    label: Nutritional supplements
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0000716
    label: Depression
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplant (HSCT)
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0035088
    label: magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA)
  - id: HP:0002140
    label: ischemic stroke
  - id: HP:0001139
    label: abnormal transcranial Doppler ultrasound (TCD) results
  - id: MONDO:0006079
    label: Acute Chest Syndrome (ACS)
  - id: HP:0001945
    label: Fever
  - id: HP:0002878
    label: Acute respiratory failure
  - id: CHEBI:82594
    label: Ferritin
  - id: HP:0002204
    label: pulmonary embolism
  - id: CHEBI:50249
    label: anticoagulants
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:82557
    label: treosulfan
  - id: CHEBI:28901
    label: busulfan
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: CHEBI:63895
    label: Interleukin (IL)-6
  - id: CHEBI:197439
    label: TNFalpha
  - id: MONDO:0005502
    label: Dengue fever
  - id: HP:0003326
    label: myalgia
  - id: HP:0002027
    label: abdominal pain
  - id: HP:0002315
    label: headache
  - id: CHEBI:18050
    label: L-glutamine
  - id: MONDO:0018948
    label: Moyamoya disorder (MMD)
  - id: HP:0001250
    label: seizures
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: CHEBI:28876
    label: melphalan
  - id: CHEBI:61049
    label: tacrolimus
  - id: CHEBI:44185
    label: methotrexate
  - id: MAXO:0000004
    label: Surgical intervention
  - id: CHEBI:16335
    label: Adenosine
  - id: CHEBI:177467
    label: Opiorphin
  - id: CHEBI:17347
    label: Testosterone
  - id: MAXO:0000149
    label: hematopoietic cell transplantation (HCT)
  - id: HP:0001297
    label: Stroke
  - id: MONDO:0005151
    label: Endocrinopathy
  - id: HP:0004322
    label: short stature
  - id: HP:0000819
    label: diabetes mellitus
  - id: HP:0000135
    label: hypogonadism
  - id: HP:0000938
    label: osteopenia
  - id: HP:0000939
    label: osteoporosis
  - id: HP:0000821
    label: hypothyroidism
  - id: HP:0008163
    label: hypocortisolism
  - id: HP:0000829
    label: hypoparathyroidism
  - id: HP:0000818
    label: Endocrinopathy
  - id: MAXO:0001175
    label: Liver transplantation
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: MONDO:0013730
    label: Acute Graft-versus-Host Disease (GVHD)
  - id: HP:0001903
    label: anemia
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0000083
    label: Kidney failure
  - id: HP:0002617
    label: Vasculopathy
  - id: CHEBI:17303
    label: Morphine
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0031417
    label: rhinorrhea
  - id: HP:0012735
    label: cough
  - id: HP:0025095
    label: sneezing
  - id: HP:0002014
    label: diarrhea
  - id: CHEBI:5588
    label: Hemoglobin A (HbA)
  - id: MAXO:0000602
    label: hemodialysis
  - id: HP:0011675
    label: Arrhythmias
  - id: HP:0012418
    label: Hypoxia
  - id: HP:0001907
    label: thromboembolism
  - id: CHEBI:114786
    label: Sodium metabisulphite
  - id: CHEBI:17790
    label: Methanol
  - id: MAXO:0000127
    label: Genetic testing
  - id: CHEBI:59229
    label: GnRH antagonist
  - id: CHEBI:63533
    label: GnRH agonist
  - id: MAXO:0001490
    label: platelet transfusions
  - id: CHEBI:9168
    label: sirolimus
  - id: MAXO:0009003
    label: Preimplantation genetic testing
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0100602
    label: Preeclampsia
  - id: HP:0001622
    label: Preterm birth
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: HP:0100806
    label: Sepsis
  - id: CHEBI:41879
    label: Dexamethasone
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: HP:0001878
    label: Hemolytic anemia
  - id: HP:0002904
    label: hyperbilirubinemia
  - id: CHEBI:32026
    label: poloxamer 188
  - id: CHEBI:81579
    label: erythropoietin
  - id: MONDO:0004745
    label: Priapism
  - id: CHEBI:44915
    label: Propofol
  - id: CHEBI:28304
    label: Heparin
  - id: CHEBI:9449
    label: Terbutaline
  - id: MAXO:0000503
    label: Mechanical ventilation
  - id: MAXO:0000600
    label: Renal replacement therapy
  - id: HP:0006554
    label: Acute liver failure
  - id: HP:0100626
    label: End-stage liver disease
  - id: MONDO:0004992
    label: cancer
  - id: MONDO:0012268
    label: AIDS
  - id: MONDO:0003847
    label: genetic disorders
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:49005
    label: deferasirox
  - id: CHEBI:4356
    label: deferoxamine
  - id: CHEBI:33281
    label: antibiotics
  - id: MONDO:0011549
    label: Hyperhaemolysis syndrome (HHS)
  - id: CHEBI:29007
    label: Ceftriaxone
  - id: CHEBI:2955
    label: Azithromycin
  - id: CHEBI:2549
    label: Albuterol
  - id: CHEBI:35341
    label: steroid
  - id: HP:0004870
    label: chronic hemolytic anemia
  - id: HP:0100543
    label: cognitive dysfunction
  - id: MONDO:0019402
    label: Thalassemia Major
  - id: MONDO:0020380
    label: sickle cell anemia (SCA)
  - id: HP:0002754
    label: Osteomyelitis
  - id: HP:0001649
    label: Tachycardia
  - id: HP:0025143
    label: Chills
  - id: HP:0000790
    label: Hematuria
  - id: MONDO:0002050
    label: Depression
  - id: CHEBI:6754
    label: Meperidine
  - id: HP:0000789
    label: infertility
  - id: HP:0008209
    label: premature ovarian insufficiency
  - id: MONDO:0005096
    label: Sickle Cell Crisis (SCC)
  - id: HP:0002860
    label: SCC
  - id: CHEBI:30413
    label: Heme
  - id: CHEBI:15854
    label: Quinine
  - id: CHEBI:17245
    label: Carbon monoxide
  - id: CHEBI:17033
    label: Biliverdin
  - id: HP:0030858
    label: addiction
  - id: CHEBI:50825
    label: Gold nanoparticles (Au NPs)
  - id: CHEBI:35255
    label: chloroform
  - id: CHEBI:27750
    label: ethyl acetate
  - id: CHEBI:4775
    label: ellagic acid
  - id: CHEBI:13193
    label: 3,3',4'-tri-O-methyl ellagic acid (A)
  - id: CHEBI:27560
    label: 3,3'-di-O- methyl ellagic acid (B)
  - id: MONDO:0004995
    label: cardiovascular disease
  - id: CHEBI:125354
    label: Plerixafor
  - id: CHEBI:6129
    label: Ketorolac
  - id: CHEBI:32599
    label: Magnesium sulfate
  - id: CHEBI:6128
    label: Ketoprofen
  - id: CHEBI:5855
    label: Ibuprofen
  - id: CHEBI:6807
    label: Methadone
  - id: CHEBI:16480
    label: Nitric oxide
  - id: CHEBI:6888
    label: Methylprednisolone
  - id: MONDO:0016264
    label: Autoimmune hepatitis (AIH)
  - id: CHEBI:8378
    label: prednisolone
  - id: CHEBI:2948
    label: azathioprine
  - id: MAXO:0001128
    label: Folic Acid Supplementation
  - id: CHEBI:27470
    label: Folic Acid
  - id: CHEBI:35143
    label: Hemoglobin
  - id: MONDO:0005136
    label: Malaria
  - id: HP:0006517
    label: Poor academic performance (PAP)
  - id: MONDO:0800385
    label: Iron overload
  - id: CHEBI:63005
    label: sodium nitrate
  - id: CHEBI:29321
    label: sodium nitroprusside
  - id: CHEBI:17632
    label: nitrate
  - id: HP:0002719
    label: Susceptibility to infections
  - id: HP:0005541
    label: Sickle Cell Nephropathy (SCN)
  - id: HP:0003774
    label: End Stage Renal Disease (ESRD)
  - id: CHEBI:138181
    label: IL8
  - id: MAXO:0000487
    label: Clinical assessment
  - id: CHEBI:55379
    label: Cyclosporine (CsA)
  - id: CHEBI:4031
    label: Cyclosporine
  - id: MAXO:0000336
    label: bone marrow biopsy
  - id: HP:0033667
    label: altered mental status
  - id: HP:0001876
    label: pancytopenia
  - id: HP:0032008
    label: fat embolism
  - id: HP:0001394
    label: Cirrhosis
  - id: HP:0000952
    label: jaundice
  - id: HP:0002240
    label: hepatomegaly
  - id: HP:0001744
    label: splenomegaly
  - id: MONDO:0019180
    label: Hereditary Hemorrhagic Telangiectasia (HHT)
  - id: CHEBI:5790
    label: hydromorphone
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:35623
    label: anticonvulsants
  - id: CHEBI:35469
    label: antidepressants
  - id: CHEBI:6121
    label: ketamine
  - id: HP:0010972
    label: ineffective erythropoiesis
  - id: HP:0003077
    label: Hyperlipidemia
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0012330
    label: Pyelonephritis
  - id: HP:0001511
    label: Intrauterine growth restriction
  - id: HP:0003811
    label: Neonatal death
  - id: MAXO:0001039
    label: Cholecystectomy
  - id: HP:0001268
    label: cognitive decline
  - id: MONDO:0002280
    label: Anemia
  - id: HP:0001931
    label: Hypochromic anemia
  - id: CHEBI:18248
    label: Iron
  - id: HP:0001935
    label: microcytic anemia
  - id: HP:0002516
    label: Intracranial hypertension
  - id: CHEBI:16526
    label: Carbon dioxide (CO2)
  - id: HP:0012864
    label: abnormal sperm morphology
  - id: CHEBI:28300
    label: glutamine
  - id: CHEBI:18237
    label: Glutamic acid
  - id: CHEBI:27266
    label: Valine
  - id: CHEBI:17334
    label: Penicillin
  - id: CHEBI:22315
    label: Alkaloids
  - id: CHEBI:26848
    label: Tannins
  - id: CHEBI:22580
    label: Anthraquinones
  - id: CHEBI:15889
    label: Sterols
  - id: CHEBI:26605
    label: Saponins
  - id: CHEBI:26195
    label: Polyphenols
  - id: CHEBI:26873
    label: Terpenoids
  - id: CHEBI:15882
    label: Phenols
  - id: CHEBI:83970
    label: Cardiac glycosides
  - id: HP:0000822
    label: hypertension
  - id: HP:0002664
    label: cancer
  - id: CHEBI:51371
    label: Muscle relaxant
  - id: HP:0003394
    label: muscle spasms
  - id: CHEBI:35718
    label: Antifungal
  - id: MAXO:0010203
    label: Echocardiography
  - id: HP:0200023
    label: Priapism
  - id: HP:0000823
    label: Pubertal delay
  - id: HP:0000670
    label: Tooth decay
  - id: HP:0000805
    label: Enuresis
  - id: HP:0001638
    label: Cardiomyopathy
  - id: HP:0030157
    label: Flank pain
  - id: HP:0100749
    label: Chest pain
  - id: MONDO:0005570
    label: Hematological diseases
  - id: HP:0004444
    label: Spherocytosis
  - id: HP:0001028
    label: Hemangioma
  - id: MONDO:0005380
    label: Avascular necrosis
  - id: MAXO:0000640
    label: Corticosteroid treatment
  - id: HP:0002829
    label: Joint pain
  - id: MONDO:0006502
    label: Severe COVID-19 with acute respiratory distress syndrome (ARDS) in a sickle
      cell disease adult patient
  - id: CHEBI:8093
    label: Phenylephrine
  - id: HP:0002902
    label: Hyponatremia
  - id: CHEBI:26708
    label: Sodium
  - id: HP:0012649
    label: Increased inflammatory response
  - id: MONDO:0005354
    label: chronic hepatitis C
  - id: CHEBI:85083
    label: sofosbuvir
  - id: CHEBI:63580
    label: ribavirin
  - id: CHEBI:82977
    label: daclatasvir
  - id: CHEBI:85089
    label: ledipasvir
  - id: CHEBI:133009
    label: velpatasvir
  - id: CHEBI:132975
    label: grazoprevir
  - id: CHEBI:132967
    label: elbasvir
  - id: CHEBI:133008
    label: sofosbuvir and velpatasvir
  - id: CHEBI:71029
    label: Serum fructosamine (SF)
  - id: CHEBI:24103
    label: fructosamine
  - id: MONDO:0005015
    label: Sickle cell disease and diabetes mellitus (DM)
  - id: MONDO:0017291
    label: Reversible Cerebral Vasoconstriction Syndrome
  - id: CHEBI:36751
    label: PCA
  - id: CHEBI:81351
    label: Activin A
  - id: HP:0002326
    label: Transient ischaemic attacks
  - id: HP:0100827
    label: high lymphocyte count
  - id: HP:0001974
    label: leukocytosis
  - id: CHEBI:3423
    label: BCNU
  - id: MONDO:0005920
    label: Plasmodium falciparum malaria
  - id: CHEBI:63918
    label: artesunate
  - id: CHEBI:35480
    label: analgesics
  - id: HP:0001896
    label: reticulocytopenia
  - id: CHEBI:64360
    label: Tocilizumab
  - id: HP:0045047
    label: high percentage of hemoglobin S (HbS%)
  - id: HP:0012592
    label: Albuminuria
  - id: HP:0001915
    label: aplastic anemia
  - id: HP:0012622
    label: Chronic Kidney Disease
  - id: CHEBI:38068
    label: Antimalarials
  - id: HP:0000458
    label: anosmia
  - id: MONDO:0006260
    label: Renal medullary carcinoma
  - id: MAXO:0000194
    label: opioid analgesics
  - id: CHEBI:35475
    label: Non-steroidal anti-inflammatory drugs (NSAID)
  - id: MAXO:0010100
    label: Dietary iron restriction
  - id: MONDO:0007885
    label: osteonecrosis of the femoral head (ONFH)
  - id: CHEBI:50858
    label: corticosteroid
  - id: HP:0005743
    label: osteonecrosis of the femoral head (ONFH)
  - id: MAXO:0001006
    label: conventional complete blood count (CBC)
  - id: CHEBI:18186
    label: tyrosine
  - id: CHEBI:27897
    label: tryptophan
  - id: CHEBI:16908
    label: NADH
  - id: CHEBI:16238
    label: FAD
  - id: CHEBI:8337
    label: porphyrins
  - id: MAXO:0000011
    label: physical therapy
  - id: HP:0030838
    label: hip pain
  - id: HP:0012534
    label: Hyperalgesia
  - id: HP:0009830
    label: Neuropathy
  - id: MONDO:0018542
    label: Hyperuricemia in sickle cell nephropathy (SCN)
  - id: CHEBI:27226
    label: Uric acid
  - id: HP:0002149
    label: Hyperuricemia
  - id: CHEBI:80308
    label: Substance P
  - id: MONDO:0005632
    label: Acute Chest Syndrome
  - id: CHEBI:35523
    label: Bronchodilators
  - id: CHEBI:16962
    label: Cortisone
  - id: MAXO:0000527
    label: physical examinations
  - id: MONDO:0006507
    label: Hemochromatosis
  - id: HP:0004396
    label: Decreased appetite
  - id: HP:0001824
    label: Weight loss
  - id: HP:0002910
    label: Elevated liver enzymes
  - id: HP:0001433
    label: Hepatosplenomegaly
  - id: CHEBI:78291
    label: Iron dextran
  - id: CHEBI:30069
    label: Prussian blue
  - id: HP:0033677
    label: Acute respiratory distress syndrome
  - id: HP:0000112
    label: renal diseases
  - id: HP:0001392
    label: hepatic diseases
  - id: HP:0002321
    label: Dizziness
  - id: MAXO:0001077
    label: Splenectomy
  - id: MONDO:0014181
    label: ALS20
  - id: MAXO:0000757
    label: Infusion
  - id: HP:0011105
    label: fluid overload (FO)
  - id: HP:0000093
    label: proteinuria
  - id: CHEBI:31882
    label: N-methyl-D-aspartate
  - id: MONDO:0016222
    label: Sickle cell liver disease (SCH)
  - id: HP:0002180
    label: neurodegeneration
  - id: CHEBI:31460
    label: Deferoxamine mesylate
  - id: MONDO:0013792
    label: Intracerebral Hemorrhage
  - id: CHEBI:50924
    label: Sorafenib
  - id: HP:0004808
    label: acute myeloid leukemia
  - id: CHEBI:26020
    label: phosphate
  - id: CHEBI:17596
    label: inosine
  - id: CHEBI:15361
    label: pyruvate
  - id: CHEBI:16708
    label: adenine
  - id: CHEBI:66919
    label: Ruxolitinib
  - id: HP:0001513
    label: obesity
  - id: HP:0003119
    label: dyslipidemia
  - id: HP:0003546
    label: Exercise intolerance
